selected publications
-
academic article
- Vargas HAKramer GMScott AMWeickhardt AMeier AAParada NBeattie BJHumm JLStaton KDZanzonico PBLyashchenko SKLewis JSYaqub MSosa REvan den Eertwegh AJDavis IDAckermann UPathmaraj KSchuit RCWindhorst ADChua SWeber WALarson SMScher HILammertsma AAHoekstra OMorris MJ. Reproducibility and repeatability of semi-quantitative 18 F-fluorodihydrotestosterone (FDHT) uptake metrics in castration-resistant prostate cancer metastases: a prospective multi-center study. Journal of Nuclear Medicine. 59:jnumed.117.206490-jnumed.117.206490. 2018
- Weickhardt ANebotArkenau. Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600–mutant tumours. British Journal of Clinical Pharmacology. 2018
- Weickhardt AHamid A. Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose‐reduced 3‐weekly docetaxel for metastatic castration‐resistant prostate cancer. Asia Pacific Journal of Clinical Oncology. 2018
- Yeung YLau DKChionh FTran HTse JWTWeickhardt AJNikfarjam MScott AMTebbutt NCMariadason JM. K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines. Molecular Oncology. 11:1130-1142. 2017
- Ha FJWeickhardt AJParakh SVincent ADGlassford NJWarrillow SJones D. Survival and functional outcomes of patients with metastatic solid organ cancer admitted to the intensive care unit of a tertiary centre. Critical Care and Resuscitation. 19:159-166. 2017
- Ackerman UAckermann ULewis JSYoung KMorris MJWeickhardt ADavis IDScott AM. Fully automated synthesis of [18F]fluoro-dihydrotestosterone ([18F]FDHT) using the FlexLab module. Journal of Labelled Compounds and Radiopharmaceuticals. 59:424-428. 2016
- Price TJBruhn MALee CKHardingham JETownsend ARMann KPSimes JWeickhardt AWrin JWWilson KGebski VVan Hazel GRobinson BCunningham DTebbutt NC. Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer. British Journal of Cancer. 112:963-970. 2015
- Weickhardt AJWilliams DSLee CKChionh FSimes JMurone CWilson KParry MMAsadi KScott AMPunt CJANagtegaal IDPrice TJMariadason JMTebbutt NC. Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer. British Journal of Cancer. 113:37-45. 2015
- Aisner DLNguyen TTPaskulin DDLe ATHaney JSchulte NChionh FHardingham JMariadason JTebbutt NDoebele RCWeickhardt AJVarella-Garcia M. ROS1 and ALK Fusions in Colorectal Cancer, with Evidence of Intratumoral Heterogeneity for Molecular Drivers . Molecular Cancer Research. 12:111-118. 2014
- Weickhardt AJScheier BBurke JMGan GLu XBunn PAAisner DLGaspar LEKavanagh BDDoebele RCCamidge DR. Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 7:1807-1814. 2012
- Gan GNCamidge DRWeickhardt AJDoebele RCDzingle WScheier BKavanagh BD. Ablative Local Therapy Extends the Clinical Benefit of Crizotinib in Alk-positive Lung Cancer. International Journal of Radiation: Oncology - Biology - Physics. 84:S67-S68. 2012
- Doebele RCLu XSumey CMaxson DAWeickhardt AJOton ABBunn PABarón AEFranklin WAAisner DLVarella-Garcia MCamidge DR. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer. 118:4502-4511. 2012
- Doebele RCPilling ABAisner DLKutateladze TGLe ATWeickhardt AJKondo KLLinderman DJHeasley LEFranklin WAVarella-Garcia MCamidge DR. Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer. Clinical Cancer Research. 18:1472-1482. 2012
- Weickhardt AJPrice TJChong GGebski VPavlakis NJohns TGAzad ASkrinos EFluck KDobrovic ASalemi RScott AMMariadason JMTebbutt NC. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. Journal of Clinical Oncology. 30:1505-1512. 2012
- Weickhardt AMariadason JTebbutt NJ. Weickhardt AC. Tebbutt NM. Mariadason J. Strategies for Overcoming Inherent and Acquired Resistance to EGFR Inhibitors by Targeting Downstream Effectors in the RAS/PI3K Pathway. Current Cancer Drug Targets. 10:824-833. 2010
-
conference paper
- Price TJBruhn MLee CHardingham JTownsend ARMann KSimes JWeickhardt AJWrin JWilson KGebski VRobinson BAVan Hazel GACunningham DTebbutt NC. Correlation of PI3KCAand extended RAS gene mutation status with outcomes from the phase III AGITG MAX involving capecitabine (C) alone or in combination with bevacizumab (B) with or without mitomycin C (M) in advanced colorectal cancer (CRC).. Journal of Clinical Oncology. 2014
- Price TJHardingham JLee CWrin JTownsend ARWilson KWeickhardt AJSimes JMurone CTebbutt NC. Analysis of PTEN in patients with advanced colorectal cancer (CRC) receiving capecitabine alone or in combination with bevacizumab with or without mitomycin C in the phase III AGITG MAX trial. Journal of Clinical Oncology. 2012
- Weickhardt AJWilliams DLee CSimes JMurone CWilson KCummins MAsadi KPrice TJMariadason JTebbutt NC. Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study.. Journal of Clinical Oncology. 2011
- Price TJHardingham JELee CKWeickhardt ATownsend ARWrin JWChua AShivasami ACummins MMMurone CTebbutt NC. Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer. Journal of Clinical Oncology. 2675-2682. 2011
-
abstract
- Hodgson-Garms MMariadason JWeickhardt A. Mechanisms of acquired resistance to the fibroblast growth factor receptor (FGFR) inhibitor BGJ398 in FGFR driven bladder cancer. Annals of Oncology. 2016
- Gong SJO'Keefe GJLee STAkhurst TLee FTDavis IWeickhardt AGan HPathmeraj KHicks RJHudson PJScott AM. DOSIMETRY OF I-124-PEG-AVP0458 DIABODY IN PATIENTS WITH TAG-72 POSITIVE OVARIAN OR PROSTATE CANCER. Internal Medicine Journal. 40-41. 2015